GB268 / Edding Genor Group - LARVOL DELTA

A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=330 | Not yet recruiting | Sponsor: Genor Biopharma Co., Ltd.

New P1 trial • Oncology • Solid Tumor

Development of GB268, a tri-specific antibody targeting PD-1/CTLA-4/VEGF, with enhanced anti-tumor efficacy and reduced toxicity in pre-clinical studies (AACR 2024) - "Combined application of bevacizumab and PD-1/PD-L1 blockade displays durable and improved anti-tumor effects...In arthritis induction model using hPD1/hCTLA4 double KI mice, GB268 had improved tolerance than cadonilimab and at least 20-fold better safety profile than ipilimumab combined with nivolumab. GB268 is a first-in-class anti-PD-1/CTLA-4/VEGF tri-specific antibody with innovative design... GB268 is a first-in-class anti-PD-1/CTLA-4/VEGF tri-specific antibody with innovative design. Preclinical data demonstrated GB268 is very effective in provoking anti-tumor responses. At the meantime, immune-related AEs is alleviated."

IO biomarker • Preclinical • Trispecific • Cervical Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD80 • CD86